5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.62▼ | 2.62▼ | 2.67▼ | 2.84▼ | 2.44▲ |
MA10 | 2.74▼ | 2.73▼ | 2.76▼ | 2.82▼ | 2.51▲ |
MA20 | 2.80▼ | 2.85▼ | 2.86▼ | 2.56▲ | 3.78▼ |
MA50 | 2.89▼ | 2.86▼ | 2.79▼ | 2.59▲ | N/A |
MA100 | 2.87▼ | 2.59▲ | 2.48▲ | 3.89▼ | N/A |
MA200 | 2.59▲ | 2.31▲ | 2.37▲ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.031▼ | -0.043▼ | -0.052▼ | 0.050▲ | 0.691▲ |
RSI | 29.262▼ | 36.229▼ | 38.640▼ | 49.823▼ | 21.780▼ |
STOCH | 20.899 | 12.566▼ | 15.508▼ | 66.392 | 31.150 |
WILL %R | -82.540▼ | -88.172▼ | -90.598▼ | -49.495 | -73.464 |
CCI | -98.555 | -90.487 | -106.794▼ | -9.548 | -27.132 |
Thursday, June 05, 2025 04:59 PM
May 06, 2025 (GLOBE NEWSWIRE) -- OnKure The BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the ...
|
Friday, May 30, 2025 05:01 PM
Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...
|
Friday, May 09, 2025 05:00 PM
OnKure Therapeutics (NASDAQ:OKUR – Free Report) – Research analysts at Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of OnKure Therapeutics in a research note issued on ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 2.81 | 2.89 | 2.52 | 2.65 | 165,300 |
12/06/25 | 2.83 | 2.89 | 2.65 | 2.85 | 39,700 |
11/06/25 | 2.94 | 3.03 | 2.83 | 2.83 | 51,500 |
10/06/25 | 2.935 | 3.14 | 2.935 | 3.02 | 99,574 |
09/06/25 | 2.95 | 2.9978 | 2.85 | 2.87 | 74,217 |
06/06/25 | 2.87 | 2.93 | 2.85 | 2.88 | 32,500 |
05/06/25 | 2.88 | 2.95 | 2.835 | 2.86 | 40,597 |
04/06/25 | 2.69 | 2.89 | 2.69 | 2.89 | 158,031 |
03/06/25 | 2.64 | 2.8368 | 2.61 | 2.69 | 89,507 |
02/06/25 | 2.54 | 2.68 | 2.51 | 2.65 | 85,463 |
|
|
||||
|
|
||||
|
|